Boehringer Ingelheim has announced that its Phase III FIBRONEER-ILD trial examining nerandomilast met its primary endpoint, measuring lung function through forced vital capacity (FVC) at 52 weeks. While nerandomilast remains an investigational treatment and has not been approved for use, the results from this trial mark an important achievement in interstitial lung disease (ILD).
“It’s always positive to see advancements in ILD research,” said Greg Gordon, M.D., Chief Medical Officer of the SRF. “This is a great result, and we’re excited to see the future impact for people living with scleroderma.
FIBRONEER-ILD enrolled patients with scleroderma-related ILD (SSc-ILD), including those with significant, existing fibrotic lung disease. However, patients were not allowed to be on immunosuppressive agents, including Cellcept (mycophenolate), which are typically prescribed for SSc patients.
Building on this progress, nerandomilast is also being studied as part of CONQUEST—a global clinical trial launched by the Scleroderma Research Foundation. CONQUEST is currently enrolling its initial cohort of patients with SSc-ILD.
